Skip to content

Sleep Disorders in Idiopathic Pulmonary Fibrosis

Sleep Disorders in Idiopathic Pulmonary Fibrosis

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05113654
Enrollment
78
Registered
2021-11-09
Start date
2016-04-26
Completion date
2019-06-07
Last updated
2021-11-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic Pulmonary Fibrosis

Brief summary

This diagnostic observational study was conducted to (1) investigate the prevalence of sleep-related breathing disorders and other sleep disorders in idiopathic pulmonary fibrosis in comparison to COPD, (2) identify characteristics of symptomatic and prognostic significance in idiopathic pulmonary fibrosis with/without sleep disorders, and (3) evaluate different tools for their ability to assess the risk of co-existing sleep disorders in idiopathic pulmonary fibrosis.

Interventions

DIAGNOSTIC_TESTSleep study

Nocturnal polysomnography or polygraphy to assess sleep-related breathing disorder and other sleep disorders

Sponsors

Boehringer Ingelheim
CollaboratorINDUSTRY
Wissenschaftliches Institut Bethanien e.V
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Age \>=18 years * written informed consent * IPF cohort: Documented history of IPF with definite or possible UIP pattern and signs of emphysema below 10% by HRCT (IPF diagnosis according to 2011 ATS/ERS IPF guidelines) * COPD cohort: Documented history of COPD Stage II Group A or B, Stage III or IV, Group C or D (GOLD 2014)

Exclusion criteria

* Long-term oxygen therapy * Heart failure NYHA stages III and IV * Left ventricular ejection fraction ≤ 45% * Pregnancy and/or lactation * Acute and/or life-threatening illness (instable angina pectoris, acute pulmonary arterial embolism, myocardial infarction, malignant tumor requiring treatment) * Current drug or alcohol abuse * Any medical, psychological or other condition impairing the patient's ability to provide informed consent * IPF cohort: Acute exacerbation of IPF * IPF cohort: Concomitant lung/airway diseases other than IPF (signs of emphysema \>10% by HRCT) * COPD cohort: Acute exacerbation of COPD * COPD cohort: Concomitant lung/airway diseases other than COPD (e.g. Asthma bronchiale) * Healthy cohort: Documented history of structural airway or lung disease

Design outcomes

Primary

MeasureTime frameDescription
Number of patients with any kind of sleep disorder according to the International Classification of Sleep Disorders (ICSD-3)For individual assessment of sleep disorders: one night (between 5 and 9 hours), for overall number of patients: entire study duration (37 months)Sleep disorders defined by the International Classfication of Sleep Disorders are diagnosed by a single sleep study (polysomnography or polygraphy), lasting between 5 and 9 hours for each individual participant. The number of patients for whom at least one sleep disorder is diagnosed, is used to calculate the prevalence of sleep disorders among each patient group.

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026